U.S., Feb. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07436689) titled 'Long-Term Open-Label Extension Study of Oral Levosimendan' on Feb. 20.
Brief Summary: The purpose of this study is to provide continued access to treatment with oral levosimendan (TNX-103) and to describe the safety of continued use of TNX-103 in participants with pulmonary hypertension with heart failure with preserved left ventricular ejection fraction (PH-HFpEF) who received TNX-103 in a parent study.
Study Start Date: March, 2026
Study Type: INTERVENTIONAL
Condition:
Pulmonary Hypertension Associated With HFpEF
Intervention:
DRUG: TNX-103
Open-label oral levosimendan 1-3mg
Recruitment Status: ENROLLING_BY_INVITATION
Spo...